Time to Complete Retinal Vascularization After Anti-VEGF Among Preterm Neonates in Pakistan: Complete Retinal Vascularization After Anti-VEGF Among Preterm Neonates

Mariya Nazish Memon; Asadullah Jatoi; Mona Liza Mahesar; Imtiaz Gilal; Saroop Chand; Ashok Kumar Narsani

doi:10.54393/pjhs.v6i7.3255

Authors

Mariya Nazish Memon Department of Ophthalmology, Institute of Ophthalmology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Asadullah Jatoi Department of Ophthalmology, Institute of Ophthalmology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Mona Liza Mahesar Department of Ophthalmology, Institute of Ophthalmology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Imtiaz Gilal Department of Ophthalmology, Institute of Ophthalmology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Saroop Chand Department of Neonatology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan
Ashok Kumar Narsani Department of Ophthalmology, Institute of Ophthalmology, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v6i7.3255

Keywords:

Retinopathy of Prematurity, Anti-VEGF, Vascularization, Bevacizumab, Ranibizumab, Preterm Neonates

Abstract

Retinopathy of prematurity (ROP) is a leading cause of preventable blindness in children. Anti-VEGF agents are widely used for treatment, but they pose concerns regarding delayed or incomplete retinal vascularization. There is limited local data on the vascularization timeline in Pakistani preterm neonates following anti-VEGF therapy. Objectives: To determine the time required to achieve complete retinal vascularization after intravitreal anti-VEGF injection in preterm neonates with ROP and to identify clinical predictors influencing this timeline. Methods: This prospective cohort study was conducted over 1.5 years from December 2023 to May 2025 at the neonatal nursery of the Pediatric Ward, Liaquat University of Medical and Health Sciences, Jamshoro. A total of 63 preterm neonates with treatment-requiring ROP received either Bevacizumab or Ranibizumab. Demographic, clinical, and treatment-related data were collected. Time to complete vascularization and postmenstrual age (PMA) at vascularization were recorded. ANOVA was used to assess statistical differences between subgroups. Results: The mean time to complete vascularization was 10.5 ± 2.0 weeks’ post-treatment, with a PMA of 44.5 ± 2.1 weeks. Delayed vascularization (>50 weeks) occurred in 8.5% and reactivation in 6.4% of neonates. Stage 3 ROP, Zone I disease, and Bevacizumab were associated with slightly longer vascularization times, but none of these comparisons were statistically significant (p>0.05). Conclusions: Retinal vascularization typically completes within 10–12 weeks after anti-VEGF therapy. Although not statistically significant, trends suggest extended follow-up is advisable in neonates with more severe disease or ZONE I ROP.

References

Kaur K and Mikes BA. Retinopathy of Prematurity. [Updated 2025 Jun]. In: Stat Pearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.

World Health Organization. Preterm birth. WHO Fact Sheets. 2023 May 10 [cited 2025 Jun 12].

Soni M, Khatib MN, Balaraman AK, Roopashree R, Kaur M, Srivastava M et al. Mortality Projections, Regional Disparities in the Burden of Neonatal Disorders, and the Status of Achieving SDG Targets by 2030 in South Asia: Insights from the Global Burden of Disease Study 2021. Journal of Epidemiology and Global Health. 2025 Mar; 15(1): 43. doi: 10.1007/s44197-025-00359-0.

Shahid N, Kazmi T, Farhat S, Naqvi SZ, Ahmed H. A Decade of Perinatal Mortality in Pakistan: Systematic Review of Patterns and Challenges (2013–2022). Journal of Taibah University Medical Sciences. 2025 Apr; 20(2): 139-50. doi: 10.1016/j.jtumed.2025.02.008.

Roohipoor R, Torabi H, Karkhaneh R, Riazi-Eafahani M. Comparison of Intravitreal Bevacizumab Injection and Laser Photocoagulation for Type 1 Zone II Retinopathy of Prematurity. Journal of Current Ophthalmology. 2019 Mar; 31(1): 61-5. doi: 10.1016/j.joco.2018.10.008.

Nowroozzadeh MH, Sadeghi E, Shahriari-Garaee H, Badie MR, Banihashemi J, Garg SJ. An Update on Anti-Vascular Endothelial Growth Factor Treatment for Retinopathy of Prematurity. Journal of Current Ophthalmology. 2023 Apr; 35(2): 125-34. doi: 10.4103/joco.joco_38_23.

Kang HG, Choi EY, Byeon SH, Kim SS, Koh HJ, Lee SC et al. Anti-Vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes. Korean Journal of Ophthalmology. 2018 Nov; 32(6): 451. doi: 10.3341/kjo.2018.0011.

Zhang X, Peng J, Yang Y, Liu Y, Zhang W, Gu VY et al. Vascular Development Analysis: A Study for Tertiary Anti-Vascular Endothelial Growth Factor Therapy After Second Reactivation of Retinopathy of Prematurity. Frontiers in Medicine. 2024 Jul; 11: 1421894. doi: 10.3389/fmed.2024.1421894.

Blazon MN, Rezar-Dreindl S, Wassermann L, Neumayer T, Berger A, Stifter E. Retinopathy of Prematurity: Incidence, Risk Factors, and Treatment Outcomes in A Tertiary Care Center. Journal of Clinical Medicine. 2024 Nov; 13(22): 6926. doi: 10.3390/jcm13226926.

Bakbak B, Ozturk BT, Gonul S, Gedik S. The Effect of Intravitreal Bevacizumab and Ranibizumab on Macular Edema of the Contralateral Eye: A Comparative Study of Two Anti-VEGFs. Oman Journal of Ophthalmology. 2016 Jan; 9(1): 44-8. doi: 10.4103/0974-620X.176100.

Gul N, Sethi S, Ahmad I, Mansoor A, Nadeem ZA, Najeeb W et al. Exploring Retinopathy of Prematurity: Insights from the First USAID-Funded Screening Program in KPK, Pakistan. Pakistan Journal of Medical Sciences. 2025 Jul; 41(7): 2073-9. doi: 10.12669/pjms.41.7.11021.

Alzuabi AK, Alshammari OM, Almousa AN, Abouammoh MA. Anti-Vascular Endothelial Growth Factor Therapy in Retinopathy of Prematurity: An Updated Literature Review. Saudi Journal of Ophthalmology. 2022 Jul; 36(3): 260-9. doi: 10.4103/sjopt.sjopt_12_22.

Dogra MR and Vinekar A. Role of Anti-Vascular Endothelial Growth Factor (Anti-VEGF) in the Treatment of Retinopathy of Prematurity: A Narrative Review in the Context of Middle-Income Countries. Pediatric Health, Medicine and Therapeutics. 2023 Dec: 59-69. doi: 10.2147/PHMT.S391591.

Kumawat D, Sachan A, Shah P, Chawla R, Chandra P. Aggressive Posterior Retinopathy of Prematurity: A Review on Current Understanding. Eye. 2021 Apr; 35(4): 1140-58. doi: 10.1038/s41433-021-01392-6.

Dikopf MS, Machen LA, Hallak JA, Chau FY, Kassem IS. Zone of Retinal Vascularization and Refractive Error in Premature Eyes with and without Spontaneously Regressed Retinopathy of Prematurity. Journal of American Association for Pediatric Ophthalmology and Strabismus. 2019 Aug; 23(4): 211-e1. doi: 10.1016/j.jaapos.2019.03.006.

Stahl A, Bründer MC, Lagrèze WA, Molnár FE, Barth T, Eter N et al. Ranibizumab in Retinopathy of Prematurity–One‐Year Follow‐Up of Ophthalmic Outcomes and Two‐Year Follow‐Up of Neurodevelopmental Outcomes from the CARE‐ROP Study. Acta Ophthalmologica. 2022 Feb; 100(1): e91-9. doi: 10.1111/aos.14852.

Wang AT, Gupta I, Dai S. A Review of Refractive Errors Post Anti-Vascular Endothelial Growth Factor Injection and Laser Photocoagulation Treatment for Retinopathy of Prematurity. Journal of Clinical Medicine. 2025 Jan; 14(3): 810. doi: 10.3390/jcm14030810.

Mintz-Hittner HMD, The University of Texas Health Science Center, Houston. Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity (BEAT-ROP). ClinicalTrials. Gov Identifier: NCT00622726 June. 2017; 6.

Lee CC, Chiang MC, Chu SM, Wu WC, Ho MM, Lien R. Clinical Risk Factors for Retinopathy of Prematurity Reactivation After Intravitreal Antivascular Endothelial Growth Factor Injection. The Journal of Pediatrics. 2024 Oct; 273: 113913. doi: 10.1016/j.jpeds.2024.113913

Wang SD and Zhang GM, Shenzhen Screening for Retinopathy of Prematurity Cooperative Group. Laser Therapy Versus Intravitreal Injection of Anti-VEGF Agents in Monotherapy of ROP: A Meta-Analysis. International Journal of Ophthalmology. 2020 May; 13(5): 806. doi: 10.18240/ijo.2020.05.17.